A message from the CEO

Dr Staffan Skogvall, VD

Half-yearly report

2024-01-01 to 2024-06-30

The most important thing that has happened in the last quarter is certainly that the synthesis of Phal-501 has now been completed. This is a very important milestone that was necessary to move forward in our drug project! The synthesis is complex and has required great chemical knowledge and experience. This is not only negative, but can constitute a “moat” against potential competitors. The produced substance will be used in stability tests, purity tests and toxicology evaluations in preparation for planned clinical studies. Furthermore, a GMP quality substance according to the recipe now developed will be produced for patients in the clinical studies. Preparations for future patient studies are ongoing, with the aim of initiating the first study with Phal-501 in 2025.

In the first instance, we intend to test Phal-501 for chronic bronchitis/COPD. However, there is much to suggest that the treatment may also work well for other disorders such as severe depression. I am convinced that Phal-501 will have a very beneficial effect on several diseases, and in the future will generate large revenue for PharmaLundensis!

When it comes to CleanTech Lund’s purification projects, there is a clear interest from various stakeholders. Discussions are underway for the leasing of several Minievaporators, although it is currently difficult to determine when they may be completed. I have confidence that we will eventually get good revenue from our Minievaporators!

Another potential source of income is the sale or out-licensing of CleanTech Lund’s “zero concentrate technology” for traditional evaporators. Personally, I think it is a pretty ingenious solution we have come up with to a problem that evaporators have had since the first machine was developed, namely that they always leave 5–10% of the liquid volume as residual waste. This reduces the usefulness and economic benefit of the evaporators. With our “zero concentrate technology”, for which we have patents in the U.S., Germany, the U.K. and the Nordic countries, this problem is solved. Discussions with evaporator companies on sales/out-licensing are ongoing. I would not be surprised if we can get a really good agreement!

In September, PharmaLundensis will carry out a unit issue. The money is mainly needed to continue preparations for the first clinical study with Phal-501. A part of the capital will also go to the further marketing of the Minievaporator and the out-licensing of the “zero concentrate technology”. I think we are on the verge of great revenues in PharmaLundensis!

Finally, I would also like to wish all shareholders a continued good summer and a successful fall!

Best regards,

Dr. Staffan Skogvall
CEO